Newsletter Tool

Today’s Big News

Jun 30, 2025

AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market

Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3

INmune flunks phase 2 Alzheimer's trial, focuses on subgroup efficacy to fuel partnering plans

Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA

Pfizer expands AI-powered small-molecule discovery collab with XtalPi

Pliant ends lung disease program after assessing rise in adverse events from bexotegrast trial

Sage lays off entire staff of 338 amid takeover by Supernus

FDA removes CAR-T access barriers in move set to boost cancer immunotherapy uptake

Orphan Cures Act re-added to Trump tax bill as Senate prepares to begin vote-a-rama

Featured

AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market

By Nick Paul Taylor

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline.

Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3

By Gabrielle Masson

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in a phase 3 stomach cancer trial compared to chemotherapy alone, according to the pharma.

INmune flunks phase 2 Alzheimer's trial, focuses on subgroup efficacy to fuel partnering plans

By Nick Paul Taylor

A phase 2 study of INmune Bio’s TNF inhibitor in Alzheimer’s disease has missed its primary endpoint, wiping 60% off the biotech share price.

Puerto Rico: The Bioscience Reshoring Powerhouse the Industry Can’t Afford to Miss

Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA

By James Waldron

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor candidate.

Pfizer expands AI-powered small-molecule discovery collab with XtalPi

By James Waldron

Pfizer has added another chapter to its long-running drug discovery collaboration with Chinese tech startup XtalPi, this time upgrading their molecular modeling work.

Pliant ends lung disease program after assessing rise in adverse events from bexotegrast trial

By James Waldron

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast.

Sage lays off entire staff of 338 amid takeover by Supernus

By Kevin Dunleavy

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being laid off, according to a Massachusetts Worker Adjustment and Retraining Notification.

FDA removes CAR-T access barriers in move set to boost cancer immunotherapy uptake

By Angus Liu

The FDA has removed the REMS requirements for currently approved BCMA- and CD19-directed CAR-T therapies and reduced certain post-infusion restrictions.

Orphan Cures Act re-added to Trump tax bill as Senate prepares to begin vote-a-rama

By Angus Liu

The Orphan Cures Act has been added back into the Senate version of President Donald Trump's “big, beautiful bill” after being left out in the chamber’s first rendition.

The top 10 pharma drug ad spenders of 2024

By Andrea Park,Nick Paul Taylor,Zoey Becker

The top 10 meds were responsible for about a third of all pharmaceutical advertising spending in 2024; MediaRadar reported more than $10.1 billion spent marketing all prescription drugs last year, a year-over-year increase of about 2%.

Glaukos nets European green lights for glaucoma surgery micro-stents

By Conor Hale

Glaukos said the approvals were its first under the European Union’s new and more-stringent Medical Device Regulation pathway.

22 state attorneys general reaffirm hospitals' EMTALA abortion obligation following CMS' pulled guidance

By Dave Muoio

The largely blue state legal officers said the government's rescindment of guidance on stabilizing abortion care does not change the requirements laid out in federal statute—the precise interpretation of which is still being hashed out in courts.

Fierce podcasts

Don’t miss an episode

Teva’s CEO shares ‘Pivot to Growth’ progress

In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead.

AbbVie, ADCs and the future of cancer care

Hype and hope for AI in rural healthcare

Resources

Whitepaper

How Will US Policy Impact the Growth of UK Biotech?

Presented by Blue Matter, strategic consultants in the life sciences

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.